MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer

This study is testing a new drug called AUM001 (an MNK inhibitor) combined with either an immunotherapy drug (pembrolizumab) or a chemotherapy drug (irinotecan) in people with advanced or metastatic colorectal cancer who have already received at least 2 prior treatment lines. **You may be eligible if...** - You are 18 or older with confirmed advanced or metastatic colorectal cancer - You have already tried at least 2 prior treatments - You have previously received standard chemotherapy regimens - You have measurable disease on imaging - Your performance status and organ function are adequate **You may NOT be eligible if...** - You have untreated brain metastases - You have a known driver mutation with an approved therapy you haven't tried - Your overall health or organ function is too poor Talk to your doctor to see if this trial is right for you.